The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
The PKB/AKT Pathway in Cancer
Abstract
PKB/AKT constitutes an important pathway that regulates the signaling of multiple essential biological processes. PTEN is a dual protein/lipid phosphatase whose main substrate is phosphatidyl-inositol,3,4,5 triphosphate (PIP3), the product of PI3K. Increases in PIP3 result in the recruitment of PDK1 and AKT to the membrane where they are activated. Furthermore, PI3K can be activated by direct binding to oncogenic Ras proteins. Many components of this pathway have been described as genetically altered in cancer. PTEN activity is lost by mutations, deletions or promoter methylation at high frequency in many primary and metastatic human cancers, and some germline mutations of PTEN are found in several familial cancer predisposition syndromes. Activating mutations of PI3K occur in human tumors and confer tumorigenic properties to cells in culture. Taken together, this evidence indicates that the AKT pathway is a promising potential target for cancer chemotherapy. Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the pathway at different points. Essentially, PI3Ks, PDK1, AKT and mTOR are heavily targeted for therapy in different ways. These proteins are kinases, which are very "druggable" targets a priori, and, according to the "addiction hypothesis", cancer cells with the activated pathway will be more dependent on its activity for their survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Regulation of p53: intricate loops and delicate balances
Oren, M., Damalas, A., Gottlieb, T. M., Michael, D., Taplick, J., Martínez-Leal, J. F., Maya, R. B.-Y., Moas, M., Seger, R., Taya, Y., et al. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01149-8 · Cited by 165
RetractedAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase
Nidai Ozes, O., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., & Donner, D. B. (1999) · Nature · doi:10.1038/43466 · Cited by 1,832
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Kohn, A. D., Summers, S. A., Birnbaum, M. J., & Roth, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31372 · Cited by 1,284
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · cited 1×
“PRAS40 associates with and negatively regulates mTORC1 signaling [70].”
BackgroundMayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B
Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., & Hawkins, P. T. (1997) · Science · doi:10.1126/science.277.5325.567 · Cited by 1,201
Ten years of protein kinase B signalling: a hard Akt to follow
Brazil, D. P., & Hemmings, B. A. (2001) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(01)01958-2 · Cited by 1,177
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
Protein Kinase C Isotypes Controlled by Phosphoinositide 3-Kinase Through the Protein Kinase PDK1
Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., & Parker, P. J. (1998) · Science · doi:10.1126/science.281.5385.2042 · Cited by 1,110
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 1×
“Similar tumorigenic properties have been observed in other tissues after PTEN conditional excision [132-136].”
BackgroundPhosphorylation and Regulation of Raf by Akt (Protein Kinase B)
Zimmermann, S., & Moelling, K. (1999) · Science · doi:10.1126/science.286.5445.1741 · Cited by 1,078
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.
Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordán, J., Bellacosa, A., Tsichlis, P. N., & Hay, N. (1997) · Genes & Development · doi:10.1101/gad.11.6.701 · Cited by 1,074
Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., McCormick, F., Tempst, P., et al. (1998) · Science · doi:10.1126/science.279.5351.710 · Cited by 1,059
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100462200 · Cited by 959
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
Liang, J., Zubovitz, J., Petrocelli, T., Kotchetkov, R., Connor, M. K., Han, K., Lee, J.-H., Ciarallo, S., Catzavelos, C., Beniston, R., et al. (2002) · Nature Medicine · doi:10.1038/nm761 · Cited by 948
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946
A Retroviral Oncogene, akt , Encoding a Serine-Threonine Kinase Containing an SH2-Like Region
Bellacosa, A., Testa, J. R., Staal, S. P., & Tsichlis, P. N. (1991) · Science · doi:10.1126/science.1833819 · Cited by 939
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
The Regulation and Activities of the Multifunctional Serine/Threonine Kinase Akt/PKB
Kandel, E. S., & Hay, N. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4690 · Cited by 869
Peng, X.-D., Xu, P.-Z., Chen, M.-L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W. S., Crawford, S. E., Coleman, K. G., et al. (2003) · Genes & Development · doi:10.1101/gad.1089403 · Cited by 826
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., Barrantes, I. D. B., Ho, A., Wakeham, A., ltie, A., Khoo, W., et al. (1998) · Current Biology · doi:10.1016/s0960-9822(07)00488-5 · Cited by 818
Sun, H., Lesche, R., Li, D.-M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., & Wu, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6199 · Cited by 796
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
PI 3-kinase, Akt and cell survival
Downward, J. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.01.002 · Cited by 783
Understanding Ras: ‘it ain’t over ’til it’s over’
Shields, J. M., Pruitt, K., McFall, A., Shaub, A., & Der, C. J. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01740-2 · Cited by 780
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H., Parsons, R., & Tonks, N. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9052 · Cited by 775
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743
The PIK3CA gene is mutated with high frequency in human breast cancers
Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S., Konishi, H., Karakas, B., Blair, B. G., Lin, C., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.994 · Cited by 665
Xia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
The complexity of Raf-1 regulation
Morrison, D. K., & Cutler, R. E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80060-9 · Cited by 635
Alessi, D. R., Barry Caudwell, F., Andjelkovic, M., Hemmings, B. A., & Cohen, P. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01370-1 · Cited by 628
Marsh, D. J., Kum, J. B., Lunetta, K. L., Bennett, M. J., Gorlin, R. J., Ahmed, S. F., Bodurtha, J., Crowe, C., Curtis, M. A., Dasouki, M., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1461 · Cited by 612
Kobayashi, T., & Cohen, P. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3390319 · Cited by 601
Mutations in a signalling pathway
Parsons, D. W., Wang, T.-L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L., Silliman, N., Ptak, J., Szabo, S., Willson, J. K. V., et al. (2005) · Nature · doi:10.1038/436792a · Cited by 599
Alessi, D. R., Kozlowski, M. T., Weng, Q.-P., Morrice, N., & Avruch, J. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70037-5 · Cited by 574
Species- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 555
Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size
Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M.-Y., Szabolcs, M., de Jong, R., Oltersdorf, T., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1869-1878.2005 · Cited by 551
Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt
Robey, R. B., & Hay, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209595 · Cited by 536
Oncogenic PI3K and its role in cancer
Samuels, Y., & Ericson, K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000198021.99347.b9 · Cited by 521
Freeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 515
Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors
Lindsley, C. W., Zhao, Z., Leister, W. H., Robinson, R. G., Barnett, S. F., Defeo-Jones, D., Jones, R. E., Hartman, G. D., Huff, J. R., Huber, H. E., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.011 · Cited by 503
Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
Garcia-Echeverria, C., & Sellers, W. R. (2008) · Oncogene · doi:10.1038/onc.2008.246 · Cited by 473
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis
Gottlieb, T. M., Leal, J. F. M., Seger, R., Taya, Y., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205181 · Cited by 472
Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease
Nelen, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1383 · Cited by 464
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463 · cited 2×
“These defects led to reduced growth, hyperinsulinemia, glucose intolerance and increased adiposity, which, however, did not progress to diabetes [159].”
BackgroundBi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., & Nussbaum, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10963 · Cited by 452
Signalling by PI3K isoforms: insights from gene-targeted mice
Vanhaesebroeck, B., Ali, K., Bilancio, A., Geering, B., & Foukas, L. C. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.02.008 · Cited by 444
Conditional Activation of Akt in Adult Skeletal Muscle Induces Rapid Hypertrophy
Lai, K.-M. V., Gonzalez, M., Poueymirou, W. T., Kline, W. O., Na, E., Zlotchenko, E., Stitt, T. N., Economides, A. N., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9295-9304.2004 · Cited by 442
Tran, H., Brunet, A., Griffith, E. C., & Greenberg, M. E. (2003) · Science's STKE · doi:10.1126/stke.2003.172.re5 · Cited by 434
Akt-dependent transformation: there is more to growth than just surviving
Plas, D. R., & Thompson, C. B. (2005) · Oncogene · doi:10.1038/sj.onc.1209097 · Cited by 429
Lum, J. J., Bui, T., Gruber, M., Gordan, J. D., DeBerardinis, R. J., Covello, K. L., Simon, M. C., & Thompson, C. B. (2007) · Genes & Development · doi:10.1101/gad.1529107 · Cited by 429
Shc and Fak Differentially Regulate Cell Motility and Directionality Modulated by Pten
Gu, J., Tamura, M., Pankov, R., Danen, E. H. J., Takino, T., Matsumoto, K., & Yamada, K. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.2.389 · Cited by 421
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice.
Stambolic, V., Tsao, M., MacPherson, D. P., Suzuki, A., Chapman, W. B., & Mak, T. W. (2000) · PubMed · Cited by 414
Tschopp, O., Yang, Z.-Z., Brodbeck, D., Dummler, B. A., Hemmings-Mieszczak, M., Watanabe, T., Michaelis, T., Frahm, J., & Hemmings, B. A. (2005) · Development · doi:10.1242/dev.01864 · Cited by 413
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407
KOBAYASHI, T., DEAK, M., MORRICE, N., & COHEN, P. (1999) · Biochemical Journal · doi:10.1042/bj3440189 · Cited by 405
PTEN, more than the AKT pathway
Blanco-Aparicio, C., Renner, O., Leal, J. F. M., & Carnero, A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm052 · Cited by 403
Self-citationKinkade, C. W., Castillo-Martin, M., Puzio-Kuter, A., Yan, J., Foster, T. H., Gao, H., Sun, Y., Ouyang, X., Gerald, W. L., Cordon-Cardo, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34764 · Cited by 391
Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene
Lesche, R., Groszer, M., Gao, J., Wang, Y., Messing, A., Sun, H., Liu, X., & Wu, H. (2002) · genesis · doi:10.1002/gene.10036 · Cited by 386
PKBα/Akt1 Acts Downstream of DNA-PK in the DNA Double-Strand Break Response and Promotes Survival
Bozulic, L., Surucu, B., Hynx, D., & Hemmings, B. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.02.024 · Cited by 386
Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth
Yang, Z.-Z., Tschopp, O., Hemmings-Mieszczak, M., Feng, J., Brodbeck, D., Perentes, E., & Hemmings, B. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302847200 · Cited by 384
Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1)
Dutil, E. M., Toker, A., & Newton, A. C. (1998) · Current Biology · doi:10.1016/s0960-9822(98)00017-7 · Cited by 381
(1999) · PubMed · Cited by 371
Cuello, M. A., Ettenberg, S. A., Clark, A. S., Keane, M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001) · PubMed · Cited by 370
Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner
Kovacina, K. S., Park, G. Y., Bae, S. S., Guzzetta, A. W., Schaefer, E., Birnbaum, M. J., & Roth, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210837200 · Cited by 364
FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal
Dijkers, P. F., Birkenkamp, K. U., Lam, E. W.-F., Thomas, N. S. B., Lammers, J.-W. J., Koenderman, L., & Coffer, P. J. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200108084 · Cited by 363
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Ellen Jackson, C., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. (2007) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 342
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas
Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E., Fults, D. W., Velculescu, V. E., Bigner, D. D., & Yan, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1170 · Cited by 337
Gu, J., Tamura, M., & Yamada, K. M. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.5.1375 · Cited by 334
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., Clardy, J., Sellers, W. R., & Silver, P. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00303-9 · Cited by 329
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Physiological roles of PKB/Akt isoforms in development and disease
Dummler, B., & Hemmings, B. A. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350231 · Cited by 316
Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., & Reddy, S. A. G. (2004) · Oncogene · doi:10.1038/sj.onc.1207902 · Cited by 303
The Akt kinase: Molecular determinants of oncogenicity
Aoki, M., Batista, O., Bellacosa, A., Tsichlis, P., & Vogt, P. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14950 · Cited by 296
Akt Signaling and Cancer: Surviving but not Moving On
Toker, A., & Yoeli-Lerner, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0743 · Cited by 295
PTEN, a unique tumor suppressor gene.
Dahia, P. L. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070115 · Cited by 283
Dummler, B., Tschopp, O., Hynx, D., Yang, Z.-Z., Dirnhofer, S., & Hemmings, B. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00722-06 · Cited by 282
Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., & Muller, W. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2203-2212.2001 · Cited by 280
WALKER, K. S., DEAK, M., PATERSON, A., HUDSON, K., COHEN, P., & ALESSI, D. R. (1998) · Biochemical Journal · doi:10.1042/bj3310299 · Cited by 278
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland
Li, G., Robinson, G. W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, N., Wagner, K.-U., Wu, D.-C., Lane, T. F., Liu, X., et al. (2002) · Development · doi:10.1242/dev.129.17.4159 · Cited by 272
Fang, G., Kim, C. N., Perkins, C. L., Ramadevi, N., Winton, E., Wittmann, S., & Bhalla, K. N. (2000) · Blood · doi:10.1182/blood.v96.6.2246 · Cited by 269
AKT activation predicts outcome in breast cancer patients treated with tamoxifen
Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A., & Bartlett, J. M. (2005) · The Journal of Pathology · doi:10.1002/path.1829 · Cited by 268
Weng, L.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.599 · Cited by 264
Jensen, C. J., Buch, M.-B., Krag, T. O., Hemmings, B. A., Gammeltoft, S., & Frödin, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27168 · Cited by 263
Zhu, J., Huang, J.-W., Tseng, P.-H., Yang, Y.-T., Fowble, J., Shiau, C.-W., Shaw, Y.-J., Kulp, S. K., & Chen, C.-S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4063 · Cited by 258
Hutchinson, J. N., Jin, J., Cardiff, R. D., Woodgett, J. R., & Muller, W. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3465 · Cited by 251
Ral-GTPases: approaching their 15 minutes of fame.
Feig, L. A. (2003) · Trends in Cell Biology · doi:10.1016/s0962-8924(03)00152-1 · Cited by 249
Cheng, X., Ma, Y., Moore, M., Hemmings, B. A., & Taylor, S. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9849 · Cited by 247
Insulin Increases the Association of Akt-2 with Glut4-containing Vesicles
Calera, M. R., Martinez, C., Liu, H., Jack, A. K. E., Birnbaum, M. J., & Pilch, P. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.13.7201 · Cited by 245
Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., & Cheng, J. Q. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.139-148.2000 · Cited by 240
Maroulakou, I. G., Oemler, W., Naber, S. P., & Tsichlis, P. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3782 · Cited by 238
Weng, L.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.3.237 · Cited by 234
Stiles, B., Groszer, M., Wang, S., Jiao, J., & Wu, H. (2004) · Developmental Biology · doi:10.1016/j.ydbio.2004.06.008 · Cited by 230
PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1
Radu, A., Neubauer, V., Akagi, T., Hanafusa, H., & Georgescu, M.-M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6139-6149.2003 · Cited by 221
Yang, Z.-Z., Tschopp, O., Di-Poï, N., Bruder, E., Baudry, A., Dümmler, B., Wahli, W., & Hemmings, B. A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10407-10418.2005 · Cited by 220
Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2
Woulfe, D., Jiang, H., Morgans, A., Monks, R., Birnbaum, M., & Brass, L. F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20267 · Cited by 216
Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)
Sato, S., Fujita, N., & Tsuruo, T. (2002) · Oncogene · doi:10.1038/sj.onc.1205225 · Cited by 206
Yu, H., Ai, Y., Yu, L., Zhou, X., Liu, J., Li, J., Xu, X., Liu, S., Chen, J., Liu, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23049 · Cited by 203
Webster, M. A., Hutchinson, J. N., Rauh, M. J., Muthuswamy, S. K., Anton, M., Tortorice, C. G., Cardiff, R. D., Graham, F. L., Hassell, J. A., & Muller, W. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.4.2344 · Cited by 200
Schrager, C. A., Schneider, D., Gruener, A. C., Tsou, H. C., & Peacocke, M. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90389-6 · Cited by 193
Ma, X., Ziel-van der Made, A. C., Autar, B., van der Korput, H. A., Vermeij, M., van Duijn, P., Cleutjens, K. B., de Krijger, R., Krimpenfort, P., Berns, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4519 · Cited by 191
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Granville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1654 · Cited by 181
DeFeo-Jones, D., Barnett, S. F., Fu, S., Hancock, P. J., Haskell, K. M., Leander, K. R., McAvoy, E., Robinson, R. G., Duggan, M. E., Lindsley, C. W., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.271.4.2 · Cited by 173
van Blitterswijk, W., & Verheij, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785294636 · Cited by 171
Baker, S. J. (2007) · Cell · doi:10.1016/j.cell.2006.12.023 · Cited by 171
Mammary gland involution is delayed by activated Akt in transgenic mice
Schwertfeger, K. L., Richert, M. M., & Anderson, S. M. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.6.0663 · Cited by 169
Mechanistic Insights into Maintenance of High p53 Acetylation by PTEN
Li, A. G., Piluso, L. G., Cai, X., Wei, G., Sellers, W. R., & Liu, X. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.028 · Cited by 169
Lindsay, Y. E., McCoull, D., Davidson, L., Leslie, N. R., Fairservice, A., Gray, A., Lucocq, J. M., & Downes, C. P. (2006) · Journal of Cell Science · doi:10.1242/jcs.000133 · Cited by 166
Kharas, M. G., Janes, M. R., Scarfone, V. M., Lilly, M. B., Knight, Z. A., Shokat, K. M., & Fruman, D. A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33337 · Cited by 163
Lim, K.-H., & Counter, C. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.014 · Cited by 159
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten
Backman, S. A., Ghazarian, D., So, K., Sanchez, O., Wagner, K.-U., Hennighausen, L., Suzuki, A., Tsao, M.-S., Chapman, W. B., Stambolic, V., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308217100 · Cited by 159
Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/− Mice
Bayascas, J. R., Leslie, N. R., Parsons, R. E., Fleming, S., & Alessi, D. R. (2005) · Current Biology · doi:10.1016/j.cub.2005.08.066 · Cited by 158
Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling
Fruman, D. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.03.014 · Cited by 154
Barnett, S., Bilodeau, M. T., & Lindsley, C. W. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026053507714 · Cited by 146
Dennis, P. B., Pullen, N., Pearson, R. B., Kozma, S. C., & Thomas, G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14845 · Cited by 142
Essential Role of AKT-1/Protein Kinase Bα in PTEN-Controlled Tumorigenesis
Stiles, B. L., Gilman, V., Khanzenzon, N., Lesche, R., Li, A., Qiao, R., Liu, X. Z., & Wu, H. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3842-3851.2002 · Cited by 139
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
Knight, Z. A., Chiang, G. G., Alaimo, P. J., Kenski, D. M., Ho, C., Coan, K., Abraham, R. T., & Shokat, K. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.022 · Cited by 137
Mechanisms of Control of Neuron Survival by the Endocannabinoid System
Galve‐Roperh, I., Aguado, T., Palazuelos, J., & Guzmán, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785740117 · Cited by 137
Chemically targeting the PI3K family
Knight, Z. A., & Shokat, K. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350245 · Cited by 134
Zhou, M., Gu, L., Findley, H. W., Jiang, R., & Woods, W. G. (2003) · PubMed · Cited by 133
Ding, H., Han, C., Zhu, J., Chen, C., & D’Ambrosio, S. M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20639 · Cited by 110
PTEN Regulates Mdm2 Expression through the P1 Promoter
Chang, C.-J., Freeman, D. J., & Wu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401488200 · Cited by 110
Novel targets of Akt, p21, and MDM2
Zhou, B. P., & Hung, M. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70128-0 · Cited by 105
Class reunion: PTEN joins the nuclear crew
Lian, Z., & Cristofano, A. D. (2005) · Oncogene · doi:10.1038/sj.onc.1209089 · Cited by 105
Genetic Background Controls Tumor Development in Pten -Deficient Mice
Freeman, D., Lesche, R., Kertesz, N. L., Wang, S., Li, G., Gao, J., Groszer, M., Martinez-Diaz, H., Rozengurt, N., THOMAS, G. V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4143 · Cited by 102
Boxer, R. B., Stairs, D. B., Dugan, K. D., Notarfrancesco, K. L., Portocarrero, C. P., Keister, B. A., Belka, G. K., Cho, H., Rathmell, J. C., Thompson, C. B., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.011 · Cited by 101
PTEN Loss Inhibits CHK1 to Cause Double Stranded-DNA Breaks in Cells
Puc, J., & Parsons, R. E. (2005) · Cell Cycle · doi:10.4161/cc.4.7.1795 · Cited by 101
Xing, D., & Oršulić, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502256102 · Cited by 98
Delayed mammary gland involution in MMTV-AKT1 transgenic mice
Ackler, S., Ahmad, S., Tobias, C. A., Johnson, M. D., & Glazer, R. I. (2002) · Oncogene · doi:10.1038/sj.onc.1205052 · Cited by 98
Nakashio, A., Fujita, N., Rokudai, S., Sato, S., & TSURUO, T. (2000) · PubMed · Cited by 96
Yu, K., Toral‐Barza, L., Shi, C., Zhang, W., & Zask, A. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5334 · Cited by 92
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice
Li, Y., Podsypanina, K., Liu, X., Crane, A., Tan, L. K., Parsons, R. E., & VARMUS, H. E. (2001) · BMC Molecular Biology · doi:10.1186/1471-2199-2-2 · Cited by 82
Chemical Genetic Analysis of FOXO Nuclear–Cytoplasmic Shuttling by Using Image‐Based Cell Screening
Zanella, F., Rosado, A., García, B., Carnero, A., & Link, W. (2008) · ChemBioChem · doi:10.1002/cbic.200800255 · Cited by 82
Self-citationSürücü, B., Bozulic, L., Hynx, D., Parcellier, A., & Hemmings, B. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803053200 · Cited by 81
Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Lindsley, C. W., Stanley, B., Melissa, Y., et al. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607781696864 · Cited by 72
Knockout mouse models and mammary tumorigenesis
Deng, C., & Brodie, S. G. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0394 · Cited by 58
Nuclear PTEN: a tale of many tails
Gil, Á., Andrés‐Pons, A., & Pulido, R. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402073 · Cited by 54
Blanco‐Aparicio, C., Pérez-Gallego, L., Pequeño, B., Martínez-Leal, J. F., Renner, O., & Carnero, A. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl190 · Cited by 46
Self-citationRenner, O., Blanco-Aparicio, C., Grassow, M., Cañamero, M., Leal, J. F. M., & Carnero, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1539 · Cited by 44 · cited 1×
“We have targeted p110 to the membrane activating PI3K in transgenic mice [156,157].”
BackgroundSelf-citationTorbett, N. E., Casamassima, A., & Parker, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303532200 · Cited by 42
Phosphoinositide breakdown and evidence for protein kinase C involvement during human NK killing
Chow, S. C., Ng, J., Nordstedt, C., et al. (1988) · Cellular Immunology · doi:10.1016/0008-8749(88)90257-2 · Cited by 40
Carnero, A., & Beach, D. (2004) · Oncogene · doi:10.1038/sj.onc.1207839 · Cited by 39
Self-citationBlocking the PI3K/PKB Pathway in Tumor Cells
Stauffer, F., Holzer, P. D., & Garcı́a-Echeverrı́a, C. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011054866937 · Cited by 39
Fecteau, K. A., Mei, J., & Wang, H. R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.890 · Cited by 38
Link, W., Rosado, A., Fominaya, J. M., Thomas, J. E., & Carnero, A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20479 · Cited by 36
Self-citationDierov, J. K., Xu, Q., Dierova, R., & Carroll, M. P. (2002) · Blood · doi:10.1182/blood.v99.5.1758 · Cited by 33
Ras Signaling, Deregulation of Gene Expression and Oncogenesis
Ülkü, A. S., & Der, C. J. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-48158-8_8 · Cited by 33
A new mouse model of pancreatic cancer: PTEN gets its Akt together
Maitra, A., & Hruban, R. H. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.007 · Cited by 32
Genetic Alterations in Esophageal Cancer
Okano, J., Snyder, L. C., & Rustgi, A. K. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:131 · Cited by 29
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate
Renner, O., Fominaya, J. M., Alonso, S. R., Blanco‐Aparicio, C., Martínez-Leal, J. F., & Carnero, A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm059 · Cited by 25
Self-citationGenetic modelling of the PTEN/AKT pathway in cancer research
Renner, O., Blanco‐Aparicio, C., & Carnero, A. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0262-1 · Cited by 23
Self-citationChen, L., Yao, X., & Nyomba, B. L. G. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01098.2004 · Cited by 21
Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas
McFarlin, D. R., Lindstrom, M. J., & Gould, M. N. (2003) · Carcinogenesis · doi:10.1093/carcin/24.1.99 · Cited by 13
McFarlin, D. R. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg045 · Cited by 12
Cited by
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
Schiliro, C., & Firestein, B. L. (2021) · Cells · doi:10.3390/cells10051056 · Cited by 615
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Neuronal Intrinsic Mechanisms of Axon Regeneration
Liu, K., Tedeschi, A., Park, K. K., & He, Z. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113723 · Cited by 458
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Metadata
- Authors
- Carnero, A.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 16
- Issue
- 1
- Pages
- 34-44
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1980886592
- Cited by
- 272
- References
- 186
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.